Guide to EU Pharmaceutical Regulatory Law

Edited By

Sally Shorthose, Bird & Bird LLP
# Summary of Contents

About the Editor and Authors v

Foreword xix

List of Terms and Abbreviations xlix

**CHAPTER 1**
Overview of European Pharmaceutical Regulatory Requirements
*Sally Shorthose* 1

**CHAPTER 2**
Clinical Trials
*Sally Shorthose* 27

**CHAPTER 3**
Obtaining a Marketing Authorisation
*Sally Shorthose & Sarah Faircliffe* 105

**CHAPTER 4**
Conditional Marketing Authorisations
*Sally Shorthose* 141

**CHAPTER 5**
Supplementary Protection Certificates
*Lorna Brazell* 155
CHAPTER 6
Paediatrics
Sally Shorthose & Sarah Faircliffe

CHAPTER 7
Advertising Medicinal Products for Human Use
Mary Smillie (main chapter & UK), Marc Martens & Nicolas Carbonnelle (Belgium), Diane Bandon-Tourret (France), Ulf Grundmann & Elisabeth Kohoutek (Germany), Machtedt Hiemstra (Netherlands), Mauro Turrini (Italy), Ida Smed Sörensen (Sweden) & Raquel Ballesteros (Spain)

CHAPTER 8
Pharmacovigilance
Sally Shorthose

CHAPTER 9
Variations to Marketing Authorisations
Lorna Brazell

CHAPTER 10
Combination Products
Ina vom Feld

CHAPTER 11
Abridged Procedure
Sally Shorthose

CHAPTER 12
Orphan Drug Protection
Sarah Faircliffe

CHAPTER 13
Biologics
Elizabeth Fuller

CHAPTER 14
Homeopathic, Herbal, and Traditional Herbal Medicinal Products
Colette Mulder

CHAPTER 15
Advanced Therapy Medicinal Products
Marc Martens & Nicolas Carbonnelle
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Medical Devices</td>
<td>Ulf Grundmann &amp; Elisabeth Kohoutek</td>
<td>461</td>
</tr>
<tr>
<td>17</td>
<td>Parallel Trade</td>
<td>Ina vom Feld</td>
<td>507</td>
</tr>
<tr>
<td>18</td>
<td>Competition Law in the Pharmaceutical Sector</td>
<td>José Rivas &amp; Geoffroy van de Walle de Ghelcke</td>
<td>539</td>
</tr>
<tr>
<td></td>
<td><strong>Appendices</strong></td>
<td></td>
<td>567</td>
</tr>
<tr>
<td>1</td>
<td>Useful Links</td>
<td></td>
<td>569</td>
</tr>
<tr>
<td>2</td>
<td>An Example of an SmPC – For Atenolol</td>
<td></td>
<td>571</td>
</tr>
<tr>
<td>3</td>
<td>An Example of a SUSAR Form</td>
<td></td>
<td>579</td>
</tr>
<tr>
<td>4</td>
<td>An Example of a Trial Protocol</td>
<td></td>
<td>587</td>
</tr>
<tr>
<td>5</td>
<td>Required Table of Contents for the Investigator’s Brochure</td>
<td></td>
<td>605</td>
</tr>
<tr>
<td></td>
<td><strong>Table of Cases</strong></td>
<td></td>
<td>607</td>
</tr>
<tr>
<td></td>
<td>Directives</td>
<td></td>
<td>617</td>
</tr>
<tr>
<td></td>
<td>Other Legislation</td>
<td></td>
<td>621</td>
</tr>
<tr>
<td></td>
<td>Regulations</td>
<td></td>
<td>623</td>
</tr>
<tr>
<td></td>
<td><strong>Index</strong></td>
<td></td>
<td>627</td>
</tr>
</tbody>
</table>